| DB ID | MyCo_2964 |
| Title | Value of Candida serum markers in patients with invasive candidiasis after myeloablative chemotherapy |
| Year | 2009 |
| PMID | 19631094 |
| Fungal Diseases involved | Invasive candidiasis |
| Associated Medical Condition | None |
| Genus | Candida |
| Species | tropicalis |
| Organism | Candida tropicalis |
| Ethical Statement | None |
| Site of Infection | None |
| Opportunistic invasive | Invasive |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | Platelia Ag + BDG |
| Biomarker Full Name | Platelia Antigen + 1-3-beta-D-Glucan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | The Netherlands |
| Cohort | The patient group with a microbiologically proven invasive Candida infection included 21 patients (13 male, 8 female) with a mean age of 40 years (range, 3–65 years). |
| Cohort No. | 21 |
| Age Group | Mar-65 |
| P Value | None |
| Sensitivity | 0.5 |
| Specificity | 1 |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | None |
| Technique | ELISA |
| Analysis Method | FDA Approved -Platelia Aspergillus Ag ELISA+FDA Approved-Fungitell assay |
| ELISA kits | None |
| Assay Data | None |
| Validation Techniques used | FDA Approved-Fungitell assay, FDA Approved -Platelia Aspergillus Ag ELISA, ELISA |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
